Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05521191
Other study ID # RGLS8429-02
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date October 6, 2022
Est. completion date June 2025

Study information

Verified date April 2024
Source Regulus Therapeutics Inc.
Contact Kristen Gillotti
Phone 858-202-6300
Email kgillotti@regulusrx.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary Objectives - To assess the safety and tolerability of RGLS8429 - To assess the impact of RGLS8429 on ADPKD biomarkers Secondary Objectives - To assess the impact of RGLS8429 on height-adjusted total kidney volume (htTKV) - To characterize the pharmacokinetic (PK) properties of RGLS8429 - To assess the impact of RGLS8429 on renal function


Description:

This is a randomized, double-blind, placebo-controlled multiple ascending dose and an open-label fixed-dose Phase 1b study consisting of two parts, Part A and Part B. In Part A, multiple ascending doses of RGLS8429 or placebo will be administered via subcutaneous injection to subjects with ADPKD to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of RGLS8429. In Part B, a fixed-dose of RGLS8429 will be administered via subcutaneous injection to subjects with ADPKD to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of RGLS8429.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date June 2025
Est. primary completion date April 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Key Inclusion Criteria: 1. Male or female ADPKD patients, 18 to 70 years old 2. Class 1C, 1D, or 1E Mayo Imaging Classification of ADPKD (based upon either the MRI obtained during screening, or a prior MRI obtained within 5 years of screening with documented Mayo classification) 3. eGFR between 30 to 90 mL/min/1.73 m2 4. Body mass index (BMI) 18 to 35 kg/m2 5. Must understand and consent to the study procedures explained in the ICF and be willing and able to comply with the protocol Key Exclusion Criteria: 1. Administration of tolvaptan in the 28 days before randomization 2. Subject is mentally incapacitated or has significant emotional problems 3. Any medical condition or social circumstance that, in the opinion of the Investigator, may make the subject unlikely to complete the study or comply with study procedures and requirements; or may pose a risk to the subject's safety 4. History or presence of alcoholism or drug abuse within the past 2 years prior to screening 5. Only one kidney or kidney transplant recipient 6. Participation in another clinical trial and/or exposure to any investigational drug or approved therapy for investigational use within 28 days or 5 half-lives of the investigational drug's dosing, whichever is longer, prior to dosing. The 28-day or 5-half-life windows will be calculated from the date of the last dosing in the previous study to Day 1 of the current study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
RGLS8429
Solution for subcutaneous injection
Placebo
Solution for subcutaneous injection

Locations

Country Name City State
United States Southeastern Clinical Research Institute, LLC Augusta Georgia
United States University of Maryland School of Medicine, Nephrology Baltimore Maryland
United States Northeast Clinical Research Center Bethlehem Pennsylvania
United States Amicis Research Center Beverly Hills California
United States CARE Institute Boise Idaho
United States Tufts Medical Center Boston Massachusetts
United States Research by Design, LLC Chicago Illinois
United States University of Chicago Chicago Illinois
United States CARE Institute Chubbuck Idaho
United States Horizon Research Group, LLC Coral Gables Florida
United States University of Texas Southwestern Medical Center Dallas Texas
United States National Institute of Clinical Research, Inc. Garden Grove California
United States Amicis Research Center Granada Hills California
United States The Idaho Kidney Institute Idaho Falls Idaho
United States University of Iowa Iowa City Iowa
United States Mayo Clinic - Florida Jacksonville Florida
United States University of Kansas Medical Center Jared Grantham Kidney Institute Kansas City Kansas
United States California Institute of Renal Research La Mesa California
United States Nevada Kidney Disease and Hypertension Centers Las Vegas Nevada
United States Academic Medical Research Institute Los Angeles California
United States Centricity Research Phoenix Multispecialty Mesa Arizona
United States Yale Nephrology Outpatient Clinic New Haven Connecticut
United States Elixia Orlando Florida
United States Mayo Clinic - Rochester Rochester Minnesota
United States St. Clair Nephrology Research Roseville Michigan
United States Valiance Clinical Research S. Gate California
United States Swedish Center for Comprehensive Care Seattle Washington
United States Witchita Nephrology Group, PA Wichita Kansas

Sponsors (1)

Lead Sponsor Collaborator
Regulus Therapeutics Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and tolerability of RGLS4829: Incidence of AEs Incidence of adverse events over time Baseline to Day 113
Primary Impact of RGLS8429 on ADPKD biomarkers Change from baseline in PC1, PC2, NGAL, and KIM-1 urine biomarkers Baseline to Day 113
Secondary Impact of RGLS8429 on height-adjusted total kidney volume (htTKV) Change from baseline in htTKV Baseline to Day 113
Secondary Pharmacokinetic properties of RGLS8429: Cmax Maximum observed concentration (Cmax) of RGLS8429 Baseline to Day 113
Secondary Pharmacokinetic properties of RGLS8429: Tmax Time to maximum observed concentration (Tmax) of RGLS8429 Baseline to Day 113
Secondary Pharmacokinetic properties of RGLS8429: t½ Half-life of RGLS8429 (t½) Baseline to Day 113
See also
  Status Clinical Trial Phase
Completed NCT02933268 - High Water Intake in Polycystic Kidney Disease N/A
Completed NCT00759369 - Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD) N/A
Completed NCT00598377 - Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease N/A
Completed NCT01039987 - Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease N/A
Completed NCT03717883 - ADPKD Alterations in Hepatic Transporter Function
Recruiting NCT05193981 - A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD
Completed NCT03487913 - The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease Phase 2
Not yet recruiting NCT06435858 - Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease Phase 4
Recruiting NCT05190744 - PB to Treat Hereditary Nephrogenic Diabetes Insipidus, ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration Phase 2
Recruiting NCT04344769 - Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Active, not recruiting NCT02848521 - A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in Europe
Completed NCT01451827 - 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Phase 2
Completed NCT01336972 - Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD) Phase 2
Completed NCT01210560 - Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD Phase 2
Completed NCT02134899 - The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients Phase 3
Active, not recruiting NCT02729662 - Efficacy of Tolvaptan on ADPKD Patients N/A
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Recruiting NCT05288998 - Intrarenal Microvasculature in ADPKD
Recruiting NCT04939935 - Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD) Phase 3
Withdrawn NCT01988038 - Repository Study of Autosomal Dominant Polycystic Kidney Disease N/A